Article: Nicotinamide Riboside Supplementation Reduces Inflammatory Markers in Immune Cells from Healthy Subjects and Psoriasis Patients: Clinical Findings

Aug 15, 2023 Autoimmune Disease Clinical Immune Health Inflammation

Nicotinamide Riboside Supplementation Reduces Inflammatory Markers in Immune Cells from Healthy Subjects and Psoriasis Patients: Clinical Findings

Objectives

To examine how ex-vivo NR supplementation affects adaptive immunity in CD4+ T cells extracted from healthy subjects and those with mild-moderate psoriasis, and to investigate the in vivo effects of oral NR supplementation in healthy volunteers on immune responsiveness.

Journal

Cell Reports Medicine

Key Outcomes

Ex Vivo:

NAD+/NADH ratio was reduced in psoriatic T cells compared to cells from healthy subjects.
NR treatment reduced immune responsiveness in CD4+ T cells from healthy subjects and psoriasis patients.

In Vivo:

NR supplementation replicated the immune-modulating effects observed with ex-vivo NR administration, resulting in a decrease in inflammatory markers while enhancing antioxidant gene expression in immune cells.

Duration

1 week

Dose

1000 mg

Study Design

Ex Vivo:
CD4+ T cells were extracted from 12 mild-moderate psoriasis patients and healthy subjects and then treated with NR

In Vivo:
Randomized, double-blind, placebo-controlled, pilot study in 25 young, healthy subjects

See Published Study

Mitochondrial Disease

Nicotinamide Riboside Partially Restores Cellular Energy in Mitochondrial Disease: Preclinical Findings

Synopsis Mitochondrial diseases arise from genetic mutations that impair energy production in cells. One of the most common, the m.3243A>G mutation, disrupts complex I of the mitochondrial resp...

Cancer

Using Engineered Cancer Cells to Identify How Orphan Cytotoxins Work: Preclinical Findings

Synopsis Orphan cytotoxins are small molecules whose exact targets or mechanisms are unknown. Understanding how they work can reveal new research tools and potential therapies. To help identify th...